CYCC: AI 评分 43/100 — AI 分析 (4月 2026)
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other proliferative diseases. Their pipeline includes multiple Phase 1/2 clinical trials targeting various forms of leukemia, solid tumors, and other hematological malignancies.
公司概况
概要：
CYCC是做什么的？
CYCC的投资论点是什么？
CYCC在哪个行业运营？
CYCC有哪些增长机遇？
- Fadraciclib Development: Fadraciclib, a CDK inhibitor, represents a significant growth opportunity for Cyclacel. The drug is currently in Phase 1/2 clinical trials for solid tumors and in combination with venetoclax for relapsed or refractory chronic lymphocytic leukemia. Positive clinical data could lead to further development and potential commercialization, tapping into the multi-billion dollar market for cancer therapeutics. The timeline for potential market entry depends on successful trial outcomes and regulatory approvals.
- CYC140 Development: CYC140, a polo-like kinase inhibitor, is another key growth driver. Currently in Phase 1/2 clinical trials for advanced leukemias and solid tumors, CYC140 targets a different mechanism of action compared to fadraciclib. Success in these trials could expand Cyclacel's pipeline and address a broader range of cancer types. The market for leukemia and solid tumor treatments is substantial, offering significant revenue potential upon successful commercialization.
- Sapacitabine Development: Sapacitabine, an orally available prodrug of CNDAC, is in Phase 1/2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome. This drug offers a convenient oral administration route, potentially improving patient compliance and outcomes. The market for AML and MDS treatments is growing, driven by an aging population and increasing incidence rates. Successful development and commercialization of Sapacitabine could generate significant revenue for Cyclacel.
- Seliciclib Development: Seliciclib, a CDK inhibitor, is currently in Phase 2 investigator-sponsored trials for Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis. While not directly related to oncology, successful development in these indications could diversify Cyclacel's pipeline and revenue streams. The market for Cushing's disease and rheumatoid arthritis treatments is substantial, offering potential for growth and expansion beyond cancer therapeutics.
- Strategic Partnerships: Cyclacel's clinical collaboration agreement with the University of Texas MD Anderson Cancer Center represents a strategic growth opportunity. This collaboration allows Cyclacel to leverage the expertise and resources of a leading cancer center to evaluate its medicines in hematological malignancies. Further strategic partnerships with other research institutions or pharmaceutical companies could accelerate the development and commercialization of its pipeline assets.
- Market capitalization of $0.01B, reflecting its small-cap status and early stage of development.
- Negative P/E ratio of -0.11, indicating the company is currently not profitable.
- Gross margin of 18.5%, suggesting some efficiency in its research and development processes.
- Profit margin of -6714.8%, highlighting the significant expenses associated with clinical-stage drug development.
- Beta of 0.16, indicating lower volatility compared to the broader market.
CYCC提供哪些产品和服务？
- Develops medicines for the treatment of cancer.
- Focuses on therapies for other proliferative diseases.
- Conducts Phase 1/2 clinical trials for fadraciclib in solid tumors and chronic lymphocytic leukemia.
- Conducts Phase 1/2 clinical trials for CYC140 in advanced leukemias and solid tumors.
- Conducts Phase 1/2 clinical trials for Sapacitabine in acute myeloid leukemia and myelodysplastic syndrome.
- Supports Phase 2 investigator-sponsored trials for seliciclib in Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis.
- Collaborates with the University of Texas MD Anderson Cancer Center for clinical evaluations.
CYCC如何赚钱？
- Focuses on research and development of novel cancer therapies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered programs.
- Secures funding through venture capital, public offerings, and grants.
- Patients with cancer and other proliferative diseases.
- Hospitals and oncology clinics.
- Pharmaceutical companies seeking to license or acquire novel therapies.
- Research institutions and universities.
- Proprietary drug candidates with unique mechanisms of action.
- Intellectual property protection through patents and exclusivity.
- Clinical data supporting the safety and efficacy of its therapies.
- Strategic collaborations with leading research institutions.
什么因素可能推动CYCC股价上涨？
- Upcoming: Release of Phase 1/2 clinical trial data for fadraciclib in solid tumors.
- Upcoming: Release of Phase 1/2 clinical trial data for CYC140 in advanced leukemias.
- Upcoming: Initiation of new clinical trials for pipeline assets.
- Ongoing: Progression of existing clinical trials through various phases.
- Ongoing: Potential for new strategic partnerships or collaborations.
CYCC的主要风险是什么？
- Potential: Failure of clinical trials to meet endpoints.
- Potential: Regulatory delays or rejection of drug candidates.
- Potential: Competition from other companies developing similar therapies.
- Ongoing: Dependence on external funding to support operations.
- Ongoing: Intellectual property challenges and patent disputes.
CYCC的核心优势是什么？
- Diverse pipeline of clinical-stage drug candidates.
- Targeted therapies with specific mechanisms of action.
- Collaboration with a leading cancer center.
- Experienced management team with expertise in drug development.
CYCC的劣势是什么？
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failures.
- Dependence on partnerships for commercialization.
- Small number of employees.
CYCC有哪些机遇？
- Positive clinical trial results leading to regulatory approvals.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline through in-licensing or acquisition.
- Growing market for cancer therapeutics.
CYCC面临哪些威胁？
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expirations and generic competition.
- Economic downturn affecting funding availability.
CYCC的竞争对手是谁？
- Applied Molecular Transport Inc — Focuses on oral delivery of biologics. — (AMTI)
- Apogee Therapeutics Inc — Develops antibody therapies for inflammatory and immunological diseases. — (APGN)
- ESSA Pharma Inc — Develops therapies for prostate cancer. — (EPIX)
- Gelesis Holdings Inc — Develops therapies for weight management. — (GLS)
- IMV Inc — Develops immunotherapies for cancer. — (IMVIF)
Key Metrics
- MoonshotScore: 43/100
Company Profile
- CEO: Sing Ee Wong
- Headquarters: Berkeley Heights, US
- Employees: 12
- Founded: 2004
AI Insight
常见问题
What does Cyclacel Pharmaceuticals, Inc. do?
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer and other proliferative diseases. The company's pipeline includes several drug candidates in Phase 1/2 clinical trials, targeting various forms of leukemia, solid tumors, and other hematological malignancies. Cyclacel aims to address unmet medical needs in oncology by developing targeted therapies that disrupt the cell cycle and inhibit uncontrolled cell growth. Their business model involves research and development, clinical trials, and potential out-licensing or partnering for commercialization.
What do analysts say about CYCC stock?
As of March 16, 2026, there is no readily available analyst consensus on Cyclacel Pharmaceuticals (CYCC) due to its small market capitalization and early stage of development. Key valuation metrics such as P/E ratio are not meaningful due to the company's lack of profitability. Growth considerations revolve around the successful progression of its pipeline assets through clinical trials. Investors should conduct their own due diligence and carefully evaluate the risks and potential rewards associated with investing in CYCC, considering its speculative nature.
What are the main risks for CYCC?
The main risks for Cyclacel Pharmaceuticals (CYCC) are typical of clinical-stage biotech companies. These include the risk of clinical trial failures, regulatory hurdles, competition from other companies, and dependence on external funding. Specifically, the failure of fadraciclib or CYC140 to demonstrate efficacy in clinical trials would significantly impact the company's value. Additionally, delays in regulatory approvals or challenges to its intellectual property could negatively affect its prospects. The company's limited financial resources also pose a risk, as it relies on securing additional funding to continue its operations.
What is Cyclacel Pharmaceuticals, Inc.'s drug pipeline status?
Cyclacel Pharmaceuticals, Inc.'s pipeline includes fadraciclib, a CDK inhibitor in Phase 1/2 trials for solid tumors and chronic lymphocytic leukemia; CYC140, a PLK inhibitor in Phase 1/2 trials for advanced leukemias and solid tumors; Sapacitabine, a nucleoside analog in Phase 1/2 trials for acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor in Phase 2 investigator-sponsored trials for Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis. Upcoming catalysts include data releases from ongoing Phase 1/2 trials.
How does Cyclacel Pharmaceuticals, Inc. manage its intellectual property?
Cyclacel Pharmaceuticals, Inc. protects its intellectual property through a combination of patents, trade secrets, and other proprietary rights. The company seeks patent protection for its drug candidates, formulations, and methods of use. They also employ strategies to maintain the confidentiality of their research and development activities. However, the biotechnology industry is characterized by intense competition and frequent patent disputes, so Cyclacel faces the ongoing risk of challenges to its intellectual property rights.